Author: Customer Service
First quarter results 2025
HIGHLIGHTSQ1 EBITDA USD of 91 million and operating cashflow of USD 57 million
Sale of BW Pioneer for USD 125 million
Received USD 36 million arbitration settlement in April, USD 21 million recognised in EBITDA
Robust balance sheet with an equity ratio of 30.9% and USD 542 million in available liquidity
Q1 cash dividend of USD 0.063 per share
BW Opal departed the shipyard in Singapore 28 May
Full-year 2025 EBITDA guidance maintained in the range of USD 220-250 millionBW Offshore is nearing completion of the Barossa project well within the updated budget. On 28 May, the FPSO BW Opal departed the shipyard in Singapore and is currently enroute to the field where hook-up and connection will be undertaken. The FPSO is on track for first gas within the third quarter.
The Board of Directors has declared a quarterly...
Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business
Written by Customer Service on . Posted in Mergers And Acquisitions.
Press release
Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business
Vision AI activities excluded from the transactionConfirmatory offer received from the French State to acquire Eviden’s Advanced Computing business excluding newly separated Vision AI activities
Enterprise Value of €410 million including €110 million contingent earn outs, following the exclusion of Vision AI activities
Vision AI activities, contributing to more than one third of the operating margin of the formerly considered perimeter, repositioned in Eviden to structure a new business unit
The Parties aim to sign a binding agreement1 in the coming weeks, with a closing of the transaction expected in 2026Paris, France – June 2, 2025 – Following its press release dated November 25, 2024, Atos SE (“Atos”...
Ipsen S.A. – Initiation of the share buy-back program
Written by Customer Service on . Posted in Public Companies.
Regulated information
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
PARIS, FRANCE, 2 June 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan.
This program is made pursuant to the authorization granted by the Company’s Annual General Meeting, held on 21 May 2025.
ENDS
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline...
WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30
Written by Customer Service on . Posted in Public Companies.
WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 pm
Geneva, Switzerland – June 2, 2025 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, is proud to announce that it will present Faben’s holograms for the first time at Lisbon NFC. There will be a live performance by Faben as well as a live discussion with WISe.ART Art Director on stage.
Since its launch in 2021, WISe.ART, the NFT platform developed by WISeKey, has led numerous high-impact and pioneering NFT projects. Combining trusted digital identity, robust cybersecurity,...
AVTL successfully completed IPO
Written by Customer Service on . Posted in Public Companies.
AVTL successfully completed IPO
Rotterdam, the Netherlands, 02 June 2025
Today, we announce an update regarding the primary equity issue of our joint venture AVTL.
AVTL has successfully completed its IPO. The issue price for the IPO was INR 235 per share which is at the top end of the previously announced price band. The size of the primary equity issue is INR 2,800 crore (approximately EUR 290 million).
The board of AVTL issued an equivalent of 10.75% of new equity shares. As a result of the issuance of new shares, Vopak’s shareholding reduced from 47.31% to 42.23%.
AVTL commenced trading today, Monday 2 June 2025, at the National Stock Exchange of India Limited and BSE Limited.
Dick Richelle, CEO of Royal Vopak: “We are very pleased with the successful realisation of AVTL’s IPO, a significant milestone reflecting the strong...
Vodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and services
Written by Customer Service on . Posted in Public Companies.
Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and servicesThe deal entails Core modernization, expanded 5G capacity, and enhanced broadband to strengthen network reliability, service offering, and efficiency.2 June 2025Espoo, Finland – Nokia today announced a major agreement with Vodafone Qatar to lead a nationwide network modernization that will enable the operator to deliver faster, more secure, and highly adaptable 5G services to consumers and businesses across the country, while preparing the network for next-generation innovations.
In a major expansion of the two companies’ partnership, Vodafone Qatar will leverage Nokia’s end-to-end technology to boost network capacity and reduce latency while accelerating time-to-market with new capabilities and introducing...
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Written by Customer Service on . Posted in Public Companies.
Press release – No. 10 / 2025
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).
The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2...
DNO Contemplates Hybrid Bond Issue
Written by Customer Service on . Posted in Public Companies.
2 June 2025 – DNO ASA, the Norwegian oil and gas operator, today announced it has engaged Arctic Securities AS, DNB Carnegie (a part of DNB Bank ASA) and Pareto Securities AS as Joint Bookrunners to arrange fixed income investor meetings. Subject to inter alia market conditions and acceptable terms, a new subordinated hybrid bond issue may follow.
–
For further information, please contact:Media: media@dno.noInvestors: investor.relations@dno.no
–
DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Côte d’Ivoire and Yemen. More information is available at www.dno.no.
This...
WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET
Written by Customer Service on . Posted in Public Companies.
WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET
Geneva, Switzerland, June 2, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its management team will be presenting at the Maxim Group 2025 Virtual Tech Conference “Discover the Innovations Reshaping Tomorrow.”
WISeKey’s fireside chat presentation is scheduled for June 3rd at 8:30 am ET. Investors can access the live presentation via the following link: https://m-vest.com/events/tmt-06032025.
During the presentation, Carlos Moreira, WISeKey’s Founder and CEO, will provide a progress update on WISeKey’s platform as it advances through the “Year of Convergence,” integrating its subsidiaries’ cybersecurity offerings:...
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Written by Customer Service on . Posted in Public Companies.
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASEWYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US
Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio
Builds on established experience and leadership in oncology and immunology biosimilarsBasel, June 2, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are available to patients in the US starting today. WYOST® and Jubbonti® are the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of the reference medicines XGEVA®*...